Also from this source

You just read:

Isis Pharmaceuticals Earns $2.15M For Advancing ISIS-SMN Rx in Children with Spinal Muscular Atrophy

News provided by

Isis Pharmaceuticals, Inc.

Jul 14, 2015, 07:00 ET